# US 2017/0281700 A1 · Phage therapy for targeting enterococci

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2017/0281700 A1
- Document ID: US20170281700A1
- Status: Published application
- Kind: A1
- Application number: 15/623,556
- Filed: 2017-06-15
- Published: 2017-10-05
- Earliest claimed: 2014-12-17
- Assignees: Yissum Research Development Company of the Hebrew University of Jerusalem; Hadasit Medical Research Services and Development Ltd.
- Applicants: Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.; Hadasit Medical Research Services & Development Ltd.
- Inventors: Nissan Ronen HAZAN; Nurit BEYTH
- Web page: https://patentgrep.com/patent/US20170281700A1

## CPC

- A61K 35/76: Viruses; Subviral particles; Bacteriophages
- A61K 9/0034: {Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- C12N 2795/10121: Viruses as such, e.g. new isolates, mutants or their genomic sequences
- C12N 2795/10132: Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- C12N 2795/10171: Demonstrated in vivo effect
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Isolated bacteriophages having genomes comprising the nucleic acid sequences as set forth in SEQ ID NOs: 1 and 2, or variants thereof, and compositions comprising the bacteriophages in a ratio ranging from 1:10 to 10:1, respectively. Further provided are uses of the compositions in treating or preventing an infection inflicted by a bacteria (e.g., Enterococcous faecalis and/or Enterococcous faecium). As a non-limiting example, the composition may be used in treating or preventing a root canal infection.

## Claims

### Claim 1

A composition comprising:
i. an isolated strain of bacteriophage having a genome comprising a nucleic acid sequence of SEQ ID NO: 1, or a sequence having at least 95% sequence identity thereto; and
ii. an isolated strain of bacteriophage having a genome comprising a nucleic acid sequence of SEQ ID NO: 2, or a sequence having at least 95% sequence identity thereto,
wherein a ratio between the isolated strains of bacteriophage having a genome comprising the nucleic acid sequence of SEQ ID NOs: 1 and 2 ranges from 10:1 to 1:10, respectively.

### Claim 2 (depends on 1)

The composition of claim 1, wherein the ratio between the isolated strains of bacteriophage having a genome comprising the nucleic acid sequence of SEQ ID NOs: 1 and 2 is selected from a range of: 1:1-3:1, 1:1-1:3, 3:1-1:3, 5:1-1:5 and 2:1-1:2, respectively.

### Claim 3

A composition comprising one or more isolated strains of bacteriophages selected from the group consisting of:
i. an isolated strain of bacteriophage having a genome comprising a nucleic acid sequence of SEQ ID NO: 1, or a sequence having at least 95% sequence identity thereto; and
ii. an isolated strain of bacteriophage having a genome comprising a nucleic acid sequence of SEQ ID NO: 2, or a sequence having at least 95% sequence identity thereto.

### Claim 4 (depends on 1)

The composition according to claim 1, further comprising one or more antibiotic.

### Claim 5 (depends on 1)

A pharmaceutical composition comprising the composition according to claim 1 and a pharmaceutically acceptable carrier.

### Claim 6

A method for treating a subject inflicted or at risk of being inflicted with a bacterial infection, the method comprising administering to said subject an effective amount of an agent selected from the group consisting of:
a. an isolated strain of bacteriophage having a genome comprising a nucleic acid sequence of SEQ ID NO: 1, or a sequence having at least 95% sequence identity thereto; and
b. an isolated strain of bacteriophage having a genome comprising a nucleic acid sequence of SEQ ID NO: 2, or a sequence having at least 95% sequence identity thereto;
c. a combination of (a) and (b).

### Claim 7 (depends on 6)

The method of claim 6, wherein said bacterial cell is selected from the group consisting of: Enterococcous faecalis and Enterococcous faecium.

### Claim 8 (depends on 6)

The method of claim 6(c) wherein the combination comprises the isolated strains of bacteriophage having a genome comprising the nucleic acid sequence of SEQ ID NOs: 1 and 2 in a ratio ranging from 1:10 to 10:1, respectively.

### Claim 9 (depends on 8)

The method of claim 8, wherein the ratio between the isolated strains of bacteriophage having a genome comprising the nucleic acid sequence of SEQ ID NOs: 1 and 2 is selected from a range of: 1:1-3:1, 1:1-1:3, 3:1-1:3, 5:1-1:5 and 2:1-1:2, respectively.

### Claim 10 (depends on 6)

The method of claim 6, wherein said method further comprises administration one or more antibiotics.

### Claim 11 (depends on 6)

The method of claim 6, wherein said administering is ex-vivo.

### Claim 12 (depends on 6)

The method of claim 6, wherein said administering is in-vivo.

### Claim 13 (depends on 6)

The method of claim 6, wherein said bacterial infection is selected from the group consisting of: endocarditis, bacteremia, urinary tract infections (UTI), meningitis, and root canal infections.

### Claim 14 (depends on 6)

The method of claim 6, for treating or preventing a root canal infection in said subject.

### Claim 15 (depends on 14)

The method of claim 14, wherein said agent is present in a sustained release composition.

### Claim 16 (depends on 14)

The method of claim 14, wherein said pharmaceutical acceptable carrier is selected from the group consisting of: a gel, a chip, a film a non-degradable polymer and a degradable polymer.

### Claim 17 (depends on 6)

The method of claim 6, for treating or preventing urinary tract infections (UTI) in a subject.

### Claim 18 (depends on 17)

The method of claim 17, wherein said administration is directly to the urinary tract.

### Claim 19 (depends on 18)

The method of claim 18, wherein said administration is intravesical administration.
